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Trials, The ASCO recommendations about SNB, The Canadian 
SN FNAC and German SENTINA, The MD Anderson trials, and 
the ACOSOG Z 1071 and AO11202 ALLIANCE (NCTO 1901094) 
 
Results: For patients treated with NAC, patients with 
advanced stages (T3-4 /N2-3) should receive RT after 
independent NAC response. In early stages, it would be 
reasonable to receive treatment if there were residual 
disease; if doubts exist in cases of pRC, such cases should be 
assessed individually. It seems clear that patients with 
clinical regional involvement who present affectations of the 
lymph nodes following NAC will benefit from locoregional RT, 
but it is less clear in those who are pN0 following the NAC, as 
their risk of LRR is low.  
 
Conclusion: The benefit of locoregional RT is not clear in 
patients with pN0 following the NAC The ongoing NSABPB-51 
/RTOG1304 (NRG 9353) study has been designed to answer 
this question. We must wait for the results of this important 
trial. Until these results, we must follow the 
recommendations previously prescribed. 
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Purpose or Objective: To present the clinical results of ABPI 
using 3D-CRT and IG-IMRT following breast-conserving surgery 
(BCS) for early-stage breast cancer. 
 
Material and Methods: Between 2006 and 2014, 104 low risk 
breast cancer patients were treated with postoperative APBI 
given by means of 3D-CRT (n=44) using 3-5 non-coplanar, 
izocentric wedged fields, or IG-IMRT (n=60) technique using 
KVCBCT guidance for each fractions. The total dose of APBI 
was 36.9 Gy (9 x 4.1 Gy) using twice-a-day fractionation for 5 
consecutive days. Survival results, side effects, and cosmetic 
results were assessed. 
 
Results: At a median follow-up of 48 months (range: 25-112) 
one (0.9%) local recurrence was observed. Two patients 
(1.9%) died of internal disease. One (0.9%) contralateral 
recurrence and three (2.8%) secondary tumours were 
observed. Neither regional nor distant failure was detected. 
Acute side effects included grade 1 (G1) and G2 erythema in 
54 (51.9%) and 2 (1.9%), G1 parenchymal induration in 43 
(41.3%), G1 and G2 pain in 26 (25%) and 2 (1.9%) patients. No 
≥G3 or higher acute side effect occurred. Late side effects 
included G1 telangiectasia in 10 (9.6%) G1, G2, and G3 
fibrosis in 26 (25%), 3 (2.8%) and 1 (0.9%) patients 
respectively. Asymptomatic (G1) fat necrosis occurred in 8 
(7.7%) patients. The rate of excellent/good and fair/poor 
cosmetic results was 96 (92.3%), 8 (7.7%) respectively.  
 
Conclusion: Both 3D-CRT and IG-IMRT for delivery the ABPI is 
feasible and the 4 years clinical results and toxicity profile is 
comparable to other results using multicatheter APBI 
brachytherapy.  
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Purpose or Objective: Radiation and anthracyclines are 
known to induce cardiac damage. Despite the use of 3D 
planning the heart is still irradiated with non-negligible 
doses, therefore this problem needs further investigation. We 
perform an analysis of cardiac function in the left sided 
breast cancer survivors. Patients were treated with surgery 
alone (S), additional radiation (RT), additional anthracycline 
based chemotherapy (A) or both (RA).  
 
Material and Methods: A total of 140 patients were 
subjected to cardiological evaluation more than 8 years after 
primary treatment. We performed ECG and ECHO (in a part 
of patients we also had an ECG and ECHO performed before 
surgery), blood tests, chest X-ray. We also collected 
additional relevant information on patients (history, 
comorbidities, current treatment, etc.). Distribution of 
patients was as follows 50% RA arm, 18% S, 8% RT, 24% A. The 
mean time from the beginning of the treatment to 
examination was 12.2 years (8-15.9) in S, 11.7 (8-16.9) in A, 
10.7 (8-15.3) in RT, 10.1 (8.1-14.5) in RA. The majority of 
patients were treated with amputation (74%), the remaining 
with BCT. In chemotherapy arms 47% were treated with FAC, 
31% with CAF, 19% with AC, and 3% with TE. Hormonal 
treatment was given to 64% of patients, in the majority of 
them it was Tamoxifen-based. Radiotherapy dose varied 
between 50 and 70 Gy. 
 
Results: There was no significant difference in ejection 
fraction (EF) between the groups: median 56 (47-65) in S, 50 
(25-65) in A, 55 (47-62) in RT and 54 (35-67) in RA. Other 
evaluated parameters like size of the right and left ventricle, 
left atrium, thickness of septum and posterior wall also did 
not differ between groups. In the whole group in 21% of 
patients we observed chronic cardiac insufficiency. In 58% of 
patients there were other cardiovascular disorders as 
hypertension, hypercholesterolemia, atherosclerosis, 
arrhythmias, and valvular disorders. Only in one patient 
treated with radiation and chemotherapy we found impaired 
heart function without other additional causes.  
 
Conclusion: In the current series no unequivocal association 
between treatment regimen and long-term cardiac 
dysfunction could be found. Further studies in a well-
balanced patient population are needed to elucidate the 
impact of contemporary anthracycline-based systemic 
treatment and modern irradiation techniques on cardiac 
outcome.  
The research received funding from National Science Center 
Poland under grant no. N N 402 685640 
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Purpose or Objective: Incidental radiation dose to the heart 
and lung during left breast radiation therapy (RT) has been 
associated with an increased risk of cardiopulmonary 
morbidity especially in patients treated with antracyclin as 
neoadjuvant/adjuvant chemotherapy schedules after surgery. 
We conducted two different dosimetric analyses (by NTCP 
and Bio-DVH) to determine if left breast RT with the Active 
Breathing Coordinator (ABC) can reduce heart/left anterior 
descending artery (LAD) and lung dose without target 
coverage impairment. 
 
Material and Methods: Patients with stages 0-III left breast 
cancer (LBC) were enrolled and underwent simulation with 
both free breathing (FB) and ABC for comparison of 
dosimetry. ABC was used during the patient's RT course if the 
heart exposition was V(30) ≥ 12%. The prescription dose was 
50 Gy plus a boost in 88% and 2,75 Gy up to 44 Gy plus a 
boost in 22%. The primary endpoint was the magnitude of 
